Cure8 news brief
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this problem.
Adults with Crohn’s disease (especially those with perianal fistulas), patients on or considering biologic therapy, gastroenterologists, and researchers studying IBD treatments.
Johnson & Johnson reported that in the FUZION trial the proportion of patients on Tremfya 100 mg every eight weeks who achieved combined fistula remission rose from 28% at Week 24 to 35% at Week 48.
Results for the 200 mg every four weeks group were reported as stable from Week 24 to Week 48; a specific Week 48 percentage for that group was not provided in the announcement. The study enrolled patients with MRI-confirmed draining perianal fistulas and included both biologic‑naïve and biologic‑experienced participants.
Combined fistula remission in the trial was defined by clinical closure of external openings without drainage plus no underlying fluid collections on MRI. Safety through Week 48 was described as consistent with the established Tremfya profile, but the company’s announcement did not provide detailed numerical adverse event data.
This is a company announcement of Phase 3 study results presented at a conference; detailed Week 48 placebo comparisons and full numerical safety data were not included in the supplied text. The findings extend earlier 24‑week data but the report here summarizes the company presentation rather than a peer‑reviewed publication.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...
